Buqué Martinez, Aitziber

Publications

Sort by

Co-Author Network

selected publications

Cellular senescence in the response of HR⁺ breast cancer to radiotherapy and CDK4/6 inhibitors. Journal of translational medicine. 2023 Academic Article GET IT
Quantitative assessment of mitophagy in irradiated cancer cells. Methods in cell biology. 2022 Academic Article GET IT
PDIA3 epitope-driven immune autoreactivity contributes to hepatic damage in type 2 diabetes. Science immunology. 2022 Academic Article GET IT
Times cited: 8
Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis. Methods in cell biology. 2022 Academic Article GET IT
RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells. Methods in cell biology. 2022 Academic Article GET IT
Cytofluorometric assessment of acute cell death responses driven by radiation therapy. Methods in cell biology. 2022 Academic Article GET IT
Nicotinamide drives T cell activation in the mammary tumor microenvironment. Journal of translational medicine. 2022 Letter GET IT
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature reviews. Drug discovery. 2022 Review GET IT
Times cited: 30
Cytofluorometric assessment of cell cycle progression in irradiated cells. Methods in cell biology. 2022 Academic Article GET IT
Times cited: 1
Emergent impact of lifestyle on tumor progression and response to therapy. International review of cell and molecular biology. 2022 Editorial Article GET IT
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. Oncoimmunology. 2021 Academic Article GET IT
Times cited: 25
Targeting Serine in Cancer: Is Two Better Than One?. Trends in cancer. 2021 Academic Article GET IT
Times cited: 6
Immunofluorescence microscopy-based assessment of cytosolic DNA accumulation in mammalian cells. STAR protocols. 2021 Academic Article GET IT
Times cited: 3
Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER⁺ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 33
Ketosis versus carbotoxicity - metabolism determines the outcome of cancer immunotherapy. Molecular & cellular oncology. 2021 Academic Article GET IT
Times cited: 80
Preface: Chemical carcinogenesis in mice as a model of human cancer: Pros and cons. Methods in cell biology. 2021 Editorial Article GET IT
Immunomodulation by targeted anticancer agents. Cancer cell. 2020 Review GET IT
Times cited: 90
MPA/DMBA-driven mammary carcinomas. Methods in cell biology. 2020 Academic Article GET IT
Times cited: 2
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature communications. 2020 Academic Article GET IT
NK cells beat T cells at early breast cancer control. Oncoimmunology. 2020 Editorial Article GET IT
Times cited: 9
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature reviews. Clinical oncology. 2020 Review GET IT
Times cited: 457
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nature immunology. 2020 Academic Article GET IT
Times cited: 156
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature communications. 2020 Academic Article GET IT
Times cited: 58
Possible mechanisms of cancer prevention by nicotinamide. British journal of pharmacology. 2020 Review GET IT
Times cited: 8
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal for immunotherapy of cancer. 2020 Review GET IT
Times cited: 459
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology. 2020 Academic Article GET IT
Times cited: 64
Correction to: Methods to Detect Immunogenic Cell Death In Vivo. Methods in molecular biology (Clifton, N.J.). 2020 Academic Article GET IT
Methods to Detect Immunogenic Cell Death In Vivo. Methods in molecular biology (Clifton, N.J.). 2020 Academic Article GET IT
Times cited: 5
Preface-Autophagy: An old mechanism with new challenges ahead. Progress in molecular biology and translational science. 2020 Editorial Article GET IT
Times cited: 3
Today's Special on the Anticancer Menu: Immunomodulation by Antifolates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Comment GET IT
Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 83
Apoptotic caspases cut down the immunogenicity of radiation. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 20
Monitoring abscopal responses to radiation in mice. Methods in enzymology. 2019 Academic Article GET IT
Times cited: 2
Anticancer effects of anti-CD47 immunotherapy in vivo. Oncoimmunology. 2018 Academic Article GET IT
Times cited: 27
Modeling Tumor Immunology and Immunotherapy in Mice. Trends in cancer. 2018 Academic Article GET IT
Times cited: 51
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 2018 Review GET IT
Times cited: 30
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunological reviews. 2017 Review GET IT
Times cited: 61
Reply: Immunosuppressive cell death in cancer. Nature reviews. Immunology. 2017 Comment GET IT
Times cited: 12
Reply: The complement system is also important in immunogenic cell death. Nature reviews. Immunology. 2016 Letter GET IT
Times cited: 5
Immunogenic cell death in cancer and infectious disease. Nature reviews. Immunology. 2016 Review GET IT
Times cited: 1618
The ratio of CD8⁺/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 11
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology. 2016 Review GET IT
Times cited: 653
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. Cancer cell. 2016 Academic Article GET IT
Times cited: 347
Prevention of breast cancer by RANKL/RANK blockade. Cell research. 2016 Comment GET IT
Times cited: 4
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016 Review GET IT
Times cited: 40
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 46
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer cell. 2015 Review GET IT
Times cited: 1017
Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2015 Review GET IT
Times cited: 155
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology. 2015 Review GET IT
Times cited: 18
Morphometric analysis of immunoselection against hyperploid cancer cells. Oncotarget. 2015 Academic Article GET IT
Times cited: 11
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology. 2015 Review GET IT
Times cited: 122
Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology. 2015 Review GET IT
Times cited: 93
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Academic Article GET IT
eIF2α phosphorylation as a biomarker of immunogenic cell death. Seminars in cancer biology. 2015 Review GET IT
Times cited: 84
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Review GET IT
Times cited: 11
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015 Review GET IT
Times cited: 5
Classification of current anticancer immunotherapies. Oncotarget. 2014 Review GET IT
Times cited: 340
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014 Review GET IT
Times cited: 264

more ...

less ...

Background

education and training

Ph.D., University of the Basque Country (Spain) 2913
M.Sc., University of the Basque Country (Spain) 2010
M.Sc., Autonomous University of Madrid (Spain) 2006
B.Sc., University of the Basque Country (Spain) 2004

Contact

full name

Aitziber Buqué Martinez

primary email

abm2013@med.cornell.edu

VIVO Weill Cornell Medical College

Aitziber Buqué Martinez Instructor of Cell Biology in Radiation Oncology

Publications

selected publications

Background

education and training

Contact

full name

primary email